Cambridge, UK – 21st October 2015 – Cresset, innovative provider of software and contract research services for small molecule discovery and design, is pleased to announce that Cancer Therapeutics CRC (CTx), a collaborative partnership of leading research institutes, universities and biotechnology companies in Australia, has licensed the virtual screening software Blaze for cancer research.
Blaze will be used to run virtual screening projects to translate Australia’s innovative research discoveries into new cancer drugs.
“Cresset’s Blaze virtual screening platform was the obvious choice for us as it has a proven track record,” says Warwick Tong, Chief Executive Officer at CTx. “With access to a super computer at the Commonwealth Scientific and Industrial Research Organization (CSIRO) we now have the capability to run virtual screening projects not just for CTx but also as a service to all Australian academics. We look forward to working with academics and post-docs and providing them access to this impressive resource.”
“We are delighted to provide the hardware to enable CTx, and academia, to advance their goal of finding a cure for cancer.” Said Tom Peat, Senior Principal Research Scientist at CSIRO. “Collaborative research is at the heart of our ethos and together we hope to change the future for this specific disease area.”
“It’s a privilege to have been chosen by CTx to provide the software for their new virtual screening service” said Cresset’s Commercial Director, Dr David Bardsley. “Not only is it a massive endorsement of Blaze’s virtual screening capabilities, but we are proud to be supporting such an important service to Australian academia. Cresset actively supports academic research through flexible licensing terms and software bursaries. These programs enable researchers to gain low cost or free access to our cutting edge approaches thereby enhancing their research capabilities.”